FORMOSA PHARMACEUTICALS , INC
Area: Pharmaceutical and Medical Devices
Booth No: L424
Website: https://www.formosapharma.com
Exhibitor Profile
Formosa Pharmaceuticals, founded in 2010, is a late-preclinical and clinical stage biotechnology company with assets in ophthalmology, oncology, and anti-infectives.
Our Business Interests:
Seeking out-licensing or co-development opportunities for assets and technology.
* APP13007 (Ophthalmic Nanosuspension for Inflammation and Pain after Ocular Surgery) [under US FDA review]
* TSY-0110 (ADC biosimilar of Kadcyla (T-DM1)) [Late-preclinical stage]
* APNT Nanoparticle Formulation Platform
Brands
APP13007, TSY-0110, APP13002, APNT platform
Video
Exhibit Products
-
APP13002 - Infectious Eye Diseases Treatment
-
APP13007 - ophthalmic eyedrop for post-surgical ocular pain and inflammation
-
APNT Nanoparticle Formulation Platform
-
TSY-0110 - Kadcyla Biosimilar
Exhibitor Press Release
- Formosa Pharmaceuticals Announce FDA Acceptance Of NDA Filing For APP13007 2023-07-11
- Formosa Pharmaceuticals Announces Development Collaboration Agreement With Eyenovia 2023-05-08
- Formosa Pharmaceuticals Announce The NDA Submission To The US FDA For APP13007 2023-05-08
Exhibitors you may be interested in
Highest Rated